Accuray IncARAY

NasdaqHealthcareSurgical & Medical Instruments & Apparatus
Price (close)
$0.22
Market cap
$26.3M
P/E
—
Revenue (TTM)
$401.9M
Net income
-$49.2M
Dividend yield
—
1-year total return
-86.8%
Net margin
-12.2%
Revenue growth
-12.3%
Debt / equity
3.55x

What Accuray Inc does.

Accuray Incorporated is a radiation therapy company that develops, manufactures, sells and supports treatment delivery, planning, imaging and data management solutions designed to help clinical teams deliver precise radiation treatments across a broad range of clinical cases. Our portfolio includes the CyberKnife robotic platform and a differentiated helical portfolio that includes the Accuray Stellar, Radixact, Accuray Helix and Tomo C Systems, where available. We believe these solutions provide clinicians with advanced capabilities to support accuracy, flexibility, motion management, image guidance, adaptive workflows and personalized treatment delivery.

Our solutions are designed to support clinical teams during individual treatments, across the treatment workflow and throughout the patient treatment journey, from curative to palliative care. Across our robotic and helical platforms, our solutions include:

Radiation therapy systems with software-enabled motion management capabilities designed to support real-time adaptation of treatment delivery for targets that move during treatment.

Revenue and profit, by fiscal year.

Fiscal year202120222023202420252026
Revenue$396.3M$429.9M$447.6M$446.6M$458.5M$401.9M
Net income-$6.3M-$5.3M-$9.3M-$15.5M-$1.6M-$49.2M
Free cash flow$36.2M-$7.1M$2.9M-$15.5M-$1.4M-$12.8M

More on ARAY.

Figures from Accuray Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.